The Center for Biosimilars® recaps the top 5 articles for the week of May 7, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 7.
Number 5: A bibliometric analysis demonstrates that the quality and quantity of research on biosimilars is on the rise.
Number 4: Biosimilar developer Coherus announced that it has resubmitted a Biologics License Application for its pegfilgrastim biosimilar after receiving a Complete Response Letter for the drug in 2017.
Number 3: The European Medicines Agency’s 2017 report says that last year saw the agency’s highest-ever number of biosimilar applications.
Number 2: Research presented at the British Society for Rheumatology’s Annual Conference, held this month in Liverpool, United Kingdom, demonstrates that biosimilars are increasingly used as first-line treatment for juvenile idiopathic arthritis.
Number 1: Avalere has issued a new report that finds that utilization management strategies, including preferential formulary design and step therapy, are impacting the uptake of biosimilars in the United States.
Finally, last week, our e-newsletter asked for your thoughts on where the treatment of psoriasis is headed.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.